We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+16.49%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$838M
AUM Growth
+$27.2M
Cap. Flow
-$59.8M
Cap. Flow %
-7.14%
Top 10 Hldgs %
41.9%
Holding
75
New
19
Increased
15
Reduced
20
Closed
20

Top Buys

Rank Stock Value
1
A icon
Agilent Technologies
A
+$44.5M
2
BHC icon
Bausch Health
BHC
+$40.6M
3
CSLT
CASTLIGHT HEALTH, INC.
CSLT
+$34.3M
4
RAD
Rite Aid Corporation
RAD
+$23.2M
5
HCA icon
HCA Healthcare
HCA
+$22.6M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$72.5M
2
GILD icon
Gilead Sciences
GILD
+$48.6M
3
ZBH icon
Zimmer Biomet
ZBH
+$34.3M
4
CELG
Celgene Corp
CELG
+$30.9M
5
AZN icon
AstraZeneca
AZN
+$30.3M

Sector Composition

Rank Sector Weight
1 Healthcare 88.72%
2 Miscellaneous 7.42%
3 Technology 2.82%
4 Communication Services 1.03%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALGN icon
26
Align Technology
ALGN
$11.2B
$15.3M 1.82%
+294,612
New +$16.5M
ARAY icon
27
Accuray
ARAY
$32.7M
$14.2M 1.69%
1,475,360
-269,451
-15% -$2.55M
NXTM
28
DELISTED
NxStage Medical Inc.
NXTM
$13.9M 1.66%
1,090,428
+399,658
+58% +$5.21M
RCPT
29
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$13M 1.56%
310,727
-314,406
-50% -$13.5M
OXFD
30
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$12.5M 1.5%
624,869
-321,588
-34% -$6.96M
CSII
31
DELISTED
Cardiovascular Systems, Inc.
CSII
$12.4M 1.49%
+391,627
New +$12.9M
PTLA
32
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$11.7M 1.4%
+452,194
New +$12.1M
NSTG
33
DELISTED
NanoString Technologies, Inc.
NSTG
$10.9M 1.3%
528,070
-226,590
-30% -$4.32M
ELGX
34
DELISTED
Endologix Inc
ELGX
$10.2M 1.22%
79,510
+47,937
+152% +$7.45M
AKAO
35
DELISTED
Achaogen Inc
AKAO
$10.1M 1.21%
+653,700
New +$11.3M
MODN
36
DELISTED
MODEL N, INC.
MODN
$8.64M 1.03%
854,378
+763,071
+836% +$8.5M
FLXN
37
DELISTED
Flexion Therapeutics, Inc.
FLXN
$8.11M 0.97%
+493,183
New +$8.53M
XOMA
38
DELISTED
Xoma
XOMA
$7.93M 0.95%
76,127
+37,068
+95% +$5.38M
INGN icon
39
Inogen
INGN
$146M
$7.61M 0.91%
+460,923
New +$8.2M
DSCI
40
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$7.58M 0.91%
+598,077
New +$7.73M
BSTC
41
DELISTED
BioSpecifics Technologies Corp.
BSTC
$7.04M 0.84%
271,620
-14,437
-5% -$346K
RXDX
42
DELISTED
Ignyta, Inc.
RXDX
$4.98M 0.59%
+600,000
New +$5.62M
GERN icon
43
Geron
GERN
$970M
$4.41M 0.53%
+2,240,373
New +$8.93M
AMBI
44
DELISTED
Ambit Biosciences Corp
AMBI
$3.35M 0.4%
367,602
-178,383
-33% -$1.89M
VCRA
45
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$2.83M 0.34%
173,408
-110,992
-39% -$1.87M
CERS icon
46
Cerus
CERS
$534M
$2.81M 0.34%
586,205
-1,469,369
-71% -$9.44M
GNCA
47
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.28M 0.27%
+15,656
New +$1.92M
HALO icon
48
Halozyme
HALO
$12B
$815K 0.1%
+64,167
New +$952K
ISEE
49
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$692K 0.08%
19,374
-297,147
-94% -$10M
CYNO
50
DELISTED
Cynosure, Inc. Class A
CYNO
$586K 0.07%
+20,000
New +$567K
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2014 Portfolio in Review

As of Q1 2014, Redmile Group held 75 positions worth $838M, up 3.4% from $810M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group withdrew a net $59.8M in Q1 2014, closing 20 positions and reducing 20 holdings. Its most notable exit was Gilead Sciences, an estimated $48.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Redmile Group opened a new position in Agilent Technologies worth $43.2M.

  • Redmile Group's largest Q1 2014 buy was Agilent Technologies: 1,080,646 shares worth $43.2M.
  • Redmile Group added most to HCA Healthcare in Q1 2014, an estimated $22.6M increase.
  • Redmile Group's biggest Q1 2014 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $72.5M.
  • Redmile Group fully exited Gilead Sciences in Q1 2014, selling an estimated $48.6M.
  • Redmile Group's ten largest holdings make up 42% of its $838M portfolio in Q1 2014.
  • Redmile Group opened 19 new positions and closed 20 in Q1 2014.
  • Redmile Group's portfolio value rose 3.4% quarter-over-quarter to $838M.

Based on Redmile Group's 13F filing for Q1 2014, filed 15 May 2014.